Available Until 6/30/2025

Biosimilar Adoption: Past Experiences and Future Opportunities

ACPE Activity Number: NONE
Release Date: 8/1/2023
Expiration Date: 6/30/2025
CE Credits: NONE
Activity Fee: Free of charge 

Activity Overview

Biosimilar implementation provides valuable means to drive cost-effectiveness by delivering high quality biologics at a fraction of the cost.  Biosimilar agents continue to capture the majority of the market share across several therapeutic areas with utilization expected to further increase, reaching a broader patient and provider mix.  Join this discussion for considerations regarding the evaluation and optimization of biosimilar utilization and how to leverage value for your practice. 

More information on this topic can be found here:

Podcast: A New Landscape: Biosimilars in Autoimmune Indications

Podcast: A New Landscape: Biosimilars in Multiple Sclerosis

Resource Center: Biosimilar Adoption Breaking through Barriers Resource Center

The target audience includes pharmacists practicing in hospitals and health systems, especially pharmacists in decision-making roles, to assist in the implementation of biosimilars. 

After participating in this activity, learners should be able to: 

  • Summarize biosimilar definitions and key concepts. 

  • Discuss barriers and best practices in the adoption of biosimilars.  

  • Identify the role of pharmacists in biosimilar implementation. 

Jorge J. Garcia, PharmD, MHA, MBA, FACHEAssistant Vice President
Baptist Health
Miami, Florida

Aimee M. Banks, PharmD, BCPS, MSCS
Clinical Pharmacist
Vanderbilt University Medical Center
Nashville, Tennessee 

Shubha Bhat, PharmD, MS, FCCP BCACP
Clinical Pharmacy Specialist – Gastroenterology
Cleveland Clinic
Cleveland, Ohio

The following persons in control of this activity’s content have relevant financial relationships: 

Shubha Bhat Pfizer: Advisory Board, Boehringer Ingelheim: Advisory Board, Abbvie: consultant, 

Pharmacosmos: Advisory Board, Bristol Meyers Squibb: Advisory Board 

All other persons in control of content do not have any relevant financial relationships with an ineligible company.  

As defined by the Standards of Integrity and Independence in Accredited Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the activity. 

Provided by ASHP.

Sponsored in part by Amgen. Supported in part by an independent medical education grant from Sandoz Inc., a Novartis Division.